Insiders Bullish on Certain Holdings of FYT

A look at the weighted underlying holdings of the First Trust Small Cap Value AlphaDEX Fund (FYT) shows an impressive 11.0% of holdings on a weighted basis have experienced insider buying within the past six months.

START SLIDESHOW:
10 ETFs With Stocks That Insiders Are Buying »

Encore Wire Corp. ( WIRE), which makes up 0.52% of the First Trust Small Cap Value AlphaDEX Fund (FYT), has seen 2 directors and officers purchase shares in the past six months, according to the recent Form 4 data. The ETF holds a total of $317,582 worth of WIRE, making it the #80 largest holding. The table below details the recent insider buying activity observed at WIRE:

WIRE — last trade: $37.53 — Recent Insider Buys:

Purchased Insider Title Shares Price/Share Value
08/01/2014 Donald Eugene Courtney Director 5,000 $41.81 $209,050.00
10/29/2014 Gregory J. Fisher Director 1,000 $37.18 $37,180.00

And Approach Resources Inc ( AREX), the #86 largest holding among components of the First Trust Small Cap Value AlphaDEX Fund (FYT), shows 2 directors and officers as recently filing Form 4's indicating purchases. The ETF holds $297,925 worth of AREX, which represents approximately 0.49% of the ETF's total assets at last check. The recent insider buying activity observed at AREX is detailed in the table below:

AREX — last trade: $10.62 — Recent Insider Buys:

Purchased Insider Title Shares Price/Share Value
11/10/2014 Sheldon B. Lubar Director 10,000 $10.61 $106,100.00
11/13/2014 Vean J. Gregg III Director 10,000 $11.88 $118,800.00

More from Stocks

Stocks Fall Hard as Earnings Disappoint, Caterpillar Tumbles

Stocks Fall Hard as Earnings Disappoint, Caterpillar Tumbles

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Jim Cramer: If You're Afraid of the 10-Year Yield, Go to Cash

Spotify Announces Major Upgrade to Free Mobile App

Spotify Announces Major Upgrade to Free Mobile App

Looks like Coca-Cola's M&A Strategy Is Paying Off

Looks like Coca-Cola's M&A Strategy Is Paying Off

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug

Eli Lilly CEO Expresses Confidence in New Rheumatoid Arthritis Drug